P3-132: A Phase II trial of docetaxel, oxaliplatin and bevacizumab as first–line therapy of unresectable, locally advanced or recurrent and/or metastatic (Stage IIIB/IV) non–small cell lung cancer (NSCLC)– initial safety analysis

Authors :: Robert Asbury
Luis E. Raez
Timothy Webb
Nicholas Sarlis
Edgardo S. Santos
William Babcock
M. Karr
Rogelio Brito
Khaled A. Tolba
Source :: Journal of Thoracic Oncology. 2:S735
Publication Year :: 2007
Publisher :: Elsevier BV, 2007.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
Bevacizumab
business.industry
Locally advanced
non-small cell lung cancer (NSCLC)
Stage iiib
medicine.disease
First line therapy
Internal medicine
medicine
business
Docetaxel/oxaliplatin
medicine.drug

Full Text Access

Tools